Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis

References

• Belsh JM. Diagnostic challenges in ALS. Neurology. 1999; 53(5)S26–30
   PubMedGoogle Scholar
• Brooks BR. Problems in shortening the time to confirmation of ALS diagnosis: lessons from the First Consensus Conference, Chicago, May 1998. Amyotroph Lateral Scler. 2000; 1(1)S3–7
   Google Scholar
• Househam E, Swash M. Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement?. J Neurol Sci. 2000; 180: 76–81
   PubMed Web of Science ®Google Scholar
• Belsh JM, Schiffman PL. Misdiagnosis in patients with amyotrophic lateral sclerosis. Arch Intern Med. 1990; 150: 2301–5
   PubMed Web of Science ®Google Scholar
• Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry. 1996; 60: 147–51
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol. 2000; 57: 109–13
   PubMed Web of Science ®Google Scholar
• Wokke JH. Confounding effects of mimicking disorders in the early diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000; 1(1)S61–3
   Google Scholar
• Gelinas DF. Conceptual approach to diagnostic delay in ALS: a United States perspective. Neurology. 1999; 53(5)S17–9
   PubMedGoogle Scholar
• Gelinas DF. Effects of the early diagnosis of amyotrophic lateral sclerosis on the patient: advantages. Amyotroph Lateral Scler. 2000; 1(1)S73–4
   Google Scholar
• Brooks BR. Earlier is better: the benefits of early diagnosis. Neurology. 1999; 53(5)S53–4
   PubMedGoogle Scholar
• Belsh JM, Schiffman PL. The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. J Neurol Sci. 1996; 139(Suppl)110–6
   PubMed Web of Science ®Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’ workshop contributors. J Neurol Sci 1994; 124(Suppl)96–107
   PubMed Web of Science ®Google Scholar
• Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology. 1999; 52: 1311–23
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar
• ALS Association (online). Available at: http://www.alsa.org/news/article.cfm?id=1101. Accessed: September 29, 2007.
   Google Scholar
• Traynor BJ, Alexander M, Corr B, Forde C, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry. 2003; 74: 1258–61
   PubMed Web of Science ®Google Scholar
• Chio A. Update on ISIS survey: Europe, North America and South America. Amyotroph Lateral Scler. 2000; 1(1)S9–11
   Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, et al. The SLAP registry. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci. 2006; 250: 45–9
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Faglioni P, Merelli E, Sola P. The epidemiology of ALS in Modena, Italy. Neurology. 2003; 60: 683–9
   PubMed Web of Science ®Google Scholar
• del Aguila MA, Longstreth WT, Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003; 60: 813–9
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995–1997: a population-based study. Neurology. 1999; 52: 504–9
   PubMed Web of Science ®Google Scholar
• Allen KD, Kasarskis EJ, Bedlack RS, Rozear MP, Morgenlander JC, Sabet A, et al. The National Registry of Veterans with Amyotrophic Lateral Sclerosis. Neuroepidemiology. 2008; 30: 180–90
   PubMed Web of Science ®Google Scholar
• Kasarkis EJ, Dominic K, Oddone EZ. The National Registry of Veterans with Amyotrophic Lateral Sclerosis: Department of Veterans Affairs Cooperative Studies Program (CSP) #500a. Amyotroph Lateral Scler. 2004; 5(1)129–32
   Google Scholar
• Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed Poisson and negative binomial models. Psychol Bull. 1995; 118: 392–404
   PubMed Web of Science ®Google Scholar
• Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998; 50: 62–6
   PubMed Web of Science ®Google Scholar
• Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996; 39: 147–57
   PubMed Web of Science ®Google Scholar
• Dunlop J, Beal McIlvain H, She Y, Howland DS. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurol Sci. 2003; 23: 1688–96
   Google Scholar
• Kennel P, Revah F, Bohme GA, Bejuit R, Gallix P, Stutzmann JM, et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy. J Neurol Sci. 2000; 180: 55–61
   PubMed Web of Science ®Google Scholar
• Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998; 55: 526–8
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of survival. J Neurol. 2006; 253: 1428–36
   PubMed Web of Science ®Google Scholar
• Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology. 2003; 61: 750–6
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, et al. Prospective study of military service and mortality from ALS. Neurology. 2005; 64: 32–7
   PubMed Web of Science ®Google Scholar
• Horner RD, Kamins KG, Feussner JR, Grambow SC, Hoff-Lindquist J, Harati Y, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology. 2003; 61: 742–9
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, et al. The natural history of primary lateral sclerosis. Neurology. 2006; 66: 647–53
   PubMed Web of Science ®Google Scholar
• Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007; 68: 1002–7
   PubMed Web of Science ®Google Scholar